Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2024-08-27 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Telix Submits NDA for TLX101-CDx Brain Cancer Imaging Agent 3 pages 163.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 28 August 2024. It announces the submission of a New Drug Application (NDA) to the U.S. FDA for a brain cancer imaging agent, TLX101-CDx (Pixclara®). The content focuses on the regulatory filing of a drug application, describing the product, its designations, clinical context, and company background. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about a regulatory submission rather than a financial report or detailed investor presentation. It is not a report publication announcement since it contains substantive information about the NDA submission itself, not just a notice of report availability. The document fits best into the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a significant company event that does not fit other specific categories like earnings release or capital update.
2024-08-27 English
Telix Reorganisation to Deliver on Strategic Priorities 2 pages 154.7KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 27 August 2024. It announces a reorganisation and leadership changes within the company to align its operations with strategic priorities. The content focuses on management appointments and structural changes rather than financial results, detailed financial data, or regulatory filings. There is no indication that this is a full annual or interim report, audit report, earnings release, or investor presentation. The document is not a proxy solicitation, voting results, or a legal proceeding update. It is a corporate announcement about board/management changes. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (8170 characters) supports that it is a substantive announcement rather than a brief notice or report publication announcement. Confidence is high given the clear focus on leadership changes and reorganisation.
2024-08-26 English
Telix 1H 2024 Appendix 4D and Interim Report 49 pages 6.5MB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'Results Announcement for the Half Year Ended 30 June 2024' by Telix Pharmaceuticals Limited. It includes an Appendix 4D, Directors' report, and an Interim financial report for the half-year ended 30 June 2024. The content contains detailed financial data, including revenue, profit, cash flow, segment performance, and R&D expenses, as well as an auditor's review report. The document is comprehensive and covers a period shorter than a full fiscal year (half-year). It is not merely an announcement of a report but contains substantive financial statements and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-08-21 English
Telix 1H 2024 Results Release 3 pages 133.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'RESULTS ANNOUNCEMENT' and provides detailed financial results for the half-year ended 30 June 2024, including revenue, profit, cash flow, and operational highlights. It includes comprehensive financial data such as net profit after tax, gross margin, EBITDA, EBITDAR, cash generated from operations, and closing cash balance. The document also discusses strategic priorities, regulatory filings, clinical trial updates, and future guidance. The presence of detailed financial statements and analysis for a half-year period indicates this is a comprehensive interim financial report. The document length (13,175 characters) supports that it is a full report rather than a brief announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-08-21 English
Telix 1H 2024 Results Presentation 24 pages 1.3MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation containing forward-looking statements, financial highlights for H1 2024, descriptions of clinical programs, product strategies, manufacturing and supply chain updates, and references to regulatory filings and milestones. It includes financial metrics such as revenue growth, EBITDA, cash balance, and discusses strategic initiatives and product pipeline progress. The document is structured as a presentation with slides and images (omitted here), and it explicitly states it should be read in conjunction with recent reports and announcements. It does not contain full financial statements or detailed financial report data but rather summarizes performance, strategy, and outlook. This matches the definition of an Investor Presentation (IP), which focuses on financials, strategy, and market position for investors. The length (15,000 characters) and content confirm it is not a brief announcement or a regulatory filing. Therefore, the appropriate classification is Investor Presentation (IP).
2024-08-21 English
Securities Dealing Policy - Updated 11 pages 272.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 22 August 2024. It announces an update to the company's Securities Dealing Policy and includes the full text of the updated policy. The content focuses on insider trading prohibitions, definitions, and compliance requirements related to securities dealing by directors, employees, and partners. There are no financial statements, earnings data, or management discussion of financial results. The document is not a report of financial performance or a regulatory certification but a policy update announcement. It is a regulatory announcement related to compliance and governance but does not fit into categories like Annual Report, Interim Report, or Remuneration Information. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length (15,000 characters) and detailed policy text confirm it is not a brief report publication announcement or a short notice. Therefore, the classification is RNS with high confidence.
2024-08-21 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.